The MRC/BHF Heart Protection Study: preliminary results

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Pharmacology

Background:

• The Heart Protection Study (HPS) is the largest statin trial to date, enrolling over 20,500 participants.
• It specifically included high-risk individuals often excluded from prior statin trials, such as women, the elderly, and diabetics.

Purpose of the Study:

• To investigate the long-term efficacy and safety of simvastatin (40 mg daily) and an antioxidant vitamin cocktail in high-risk patients.
• To assess the impact of statin therapy on total mortality, vascular mortality, and major cardiovascular events.

Main Methods:

• A prospective, double-blind, randomized controlled trial with a 2x2 factorial design.
• Participants received either simvastatin 40 mg, an antioxidant vitamin cocktail, both, or placebo for over 5 years.
• Included patients with high coronary heart disease risk but varied baseline characteristics, including low cholesterol levels.

Main Results:

• Simvastatin 40 mg demonstrated significant benefits across all subgroups, regardless of age, gender, or baseline cholesterol.
• Reductions observed: 12% in total mortality, 17% in vascular mortality, 24% in coronary heart disease events, 27% in strokes, and 16% in non-coronary revascularizations.
• No cholesterol threshold was identified below which statin therapy was ineffective, even for those below national targets.

Conclusions:

• Long-term simvastatin 40 mg therapy is safe, well-tolerated, and highly effective in reducing mortality and major vascular events in high-risk populations.
• The antioxidant vitamin cocktail showed no significant benefit in this study.
• Statin therapy offers cardiovascular protection even in patients with lower baseline cholesterol levels.